People living with amyotrophic lateral sclerosis face a distinct set of risks when it comes to COVID-19, ranging from heightened vulnerability to severe infection to the possibility that the virus itself may worsen neurological decline. The pandemic also disrupted the specialized, team-based care that ALS patients depend on, introduced safety dilemmas around ventilation equipment, and took a measurable psychological toll on patients and their caregivers. The relationship between these two conditions is more tangled than a simple story of infection risk, touching on questions about whether SARS-CoV-2 can directly invade motor neurons and whether COVID-19 might even accelerate or trigger the disease in some people.
Why ALS Patients Are Especially Vulnerable to Severe COVID-19
ALS progressively weakens the muscles involved in breathing, swallowing, and coughing. Many patients eventually rely on non-invasive ventilation (NIV) to support their breathing, and that dependence is what makes COVID-19 so dangerous for this group. A study following ALS patients in Valencia, Spain found that those already using NIV before contracting SARS-CoV-2 had a hospitalization rate roughly fourteen times higher than non-ventilated patients. In a statistical model adjusted for age and sex, prior NIV use was an independent risk factor for hospitalization, with about a fivefold increase in odds. Of the patients who died within 30 days of infection, all had been hospitalized and most were on ventilatory support.1PubMed Central. Impact of SARS‑CoV‑2 infection and COVID‑19 pandemic on the morbidity and mortality of amyotrophic lateral sclerosis patients in Valencia, Spain
The same study found that vaccination had a strong protective effect, cutting the odds of severe infection by roughly 90 percent. Only one of the five patients who died within a month of infection had been vaccinated beforehand. That finding underscores something that applies to many neurodegenerative conditions but is especially urgent in ALS: because the disease already compromises the respiratory system, any additional respiratory insult can be devastating, and prevention through vaccination matters disproportionately.1PubMed Central. Impact of SARS‑CoV‑2 infection and COVID‑19 pandemic on the morbidity and mortality of amyotrophic lateral sclerosis patients in Valencia, Spain
Can SARS-CoV-2 Actually Infect Motor Neurons?
One of the more unsettling questions to emerge during the pandemic is whether the virus can directly infect the type of neurons that ALS destroys. The answer, at least in the lab, appears to be yes. Researchers using human motor neurons grown from induced pluripotent stem cells showed that SARS-CoV-2 could productively infect those cells. The motor neurons expressed key viral entry receptors, and the virus replicated inside them without immediately killing them. Fluid collected from the infected motor neurons was able to infect fresh cells in a follow-up experiment, confirming that the virus was actively replicating, not just passively sitting inside the neurons.2PubMed Central. Human motor neurons derived from induced pluripotent stem cells are susceptible to SARS-CoV-2 infection
Separate work on peripheral sensory neurons found a similar pattern. Human neurons derived from embryonic stem cells expressed the ACE2 receptor and were directly infected by the virus, helping explain the sensory symptoms like loss of smell and taste that many COVID-19 patients experience.3PubMed Central. Direct neuronal infection of SARS-CoV-2 reveals cellular and molecular pathology of chemosensory impairment of COVID-19 patients These findings do not prove that the virus routinely reaches and infects motor neurons in a living person. Getting from a cell culture dish to the spinal cord is a long journey. But they do establish that motor neurons are not inherently resistant to the virus, which is a meaningful starting point for understanding post-COVID neurological complications.
COVID-19 as a Possible Trigger or Accelerator of ALS
The idea that a viral infection could trigger or hasten ALS is not new to the pandemic. Researchers have long considered environmental triggers, including viral infections, as potential contributors to the disease in people who may already carry genetic or biological susceptibility. The pandemic introduced a new and very large-scale natural experiment on that question. A review of the evidence concluded that SARS-CoV-2 infection may accelerate neuroinflammatory processes already present in ALS patients and that some studies suggest the infection may have contributed to the development of the disease in previously undiagnosed individuals.4PubMed Central. Amyotrophic Lateral Sclerosis in Long-COVID Scenario and the Therapeutic Potential of the Purinergic System in Neuromodulation
Clinical case reports gave that hypothesis some individual-level support. Two patients with previously slow-progressing ALS experienced rapid functional decline after contracting COVID-19. One patient’s functional score dropped by 16 points in four months, with 11 of those points lost in the final month before death from respiratory failure. The other became wheelchair-dependent and developed speech and swallowing difficulties within months of infection, losing 5 points on the same scale compared to pre-infection assessments.5PubMed Central. COVID‐19–accelerated disease progression in two patients with amyotrophic lateral sclerosis Two cases do not establish causation, but the pattern was striking enough to prompt concern among clinicians. Both patients had been progressing slowly for years before their infections abruptly changed the trajectory.
Interestingly, a large genetic analysis looking at whether COVID-19 infection is associated with elevated risk of certain neurodegenerative diseases found a more complicated picture. COVID-19 infection was associated with a higher genetic risk of Alzheimer’s disease, but it was inversely associated with the risk of ALS. The hospitalized COVID-19 group showed no significant association with ALS risk at all.6PubMed Central. COVID-19 and the risk of Alzheimer’s disease, amyotrophic lateral sclerosis, and multiple sclerosis That finding complicates the trigger hypothesis. It suggests that whatever link exists between SARS-CoV-2 and ALS may operate through mechanisms other than shared genetic susceptibility, and that the virus’s relationship with different neurodegenerative diseases is not uniform. For someone already living with ALS, the concern remains that infection may worsen their disease, even if COVID-19 does not appear to raise the population-level genetic risk of developing it in the first place.
Is COVID-19 Vaccination Safe for People with ALS?
Given the clear benefits of vaccination in preventing severe infection, the safety question matters enormously. ALS patients and their families understandably worry about whether vaccines could worsen their neurological condition. A study examining adverse events reported after vaccination across several neurodegenerative diseases, including ALS, Parkinson’s, Alzheimer’s, and multiple sclerosis, found no statistically significant differences in the distribution of adverse events across vaccine types, including COVID-19 vaccines. The safety profile was essentially the same regardless of which neurodegenerative condition a patient had.7Brain, Behavior, & Immunity – Health. Examining vaccination-related adverse events in frequent neurodegenerative diseases
That said, the same research noted that among adverse event reports specifically from ALS patients, respiratory symptoms were prominent. COVID-19 vaccines accounted for the vast majority of reported adverse events in this group, and the most commonly flagged issues included muscular weakness, acute respiratory failure, and decreased appetite.8Brain, Behavior, & Immunity – Health. Examining vaccination-related adverse events in frequent neurodegenerative diseases – Section: 4. Results This does not mean COVID-19 vaccines cause those symptoms in ALS patients. The ALS disease process itself produces muscular weakness and respiratory failure, and these reports come from passive surveillance systems where any symptom experienced around the time of vaccination gets logged. A person whose ALS is progressing may attribute worsening symptoms to the most recent medical event, including a recent vaccination. The overall statistical analysis found no excess risk compared to other neurological populations or other vaccine types, which is the more reliable signal.
Pandemic Disruptions to ALS Care
ALS management depends heavily on coordinated, multidisciplinary in-person care. Patients typically see neurologists, respiratory therapists, speech therapists, occupational therapists, nutritionists, and palliative care specialists, often during a single clinic visit. The pandemic fractured that model almost overnight. In the United States, evidence-based treatments like feeding tubes, wheelchair fittings, home health services, and hospice care became harder to obtain and in some areas were simply unavailable. Clinical trials were also disrupted because eligibility assessments, safety monitoring, and drug dispensing all relied on face-to-face visits.9PubMed Central. Amyotrophic lateral sclerosis care and research in the United States during the COVID-19 pandemic: Challenges and opportunities
In the UK, both patients and healthcare professionals reported that care quality dropped during the pandemic. Waiting times grew longer, in-person appointments were cancelled or replaced by virtual consultations, and concerns arose that remote assessments could not fully substitute for hands-on clinical evaluations. Physical examination of breathing capacity, muscle strength, and nutritional status is difficult to replicate over video.10PubMed. Impact of the covid-19 pandemic on amyotrophic lateral sclerosis care in the UK
Telemedicine emerged as the primary workaround, and the results were genuinely mixed. A Brazilian study that tracked ALS patients through remote monitoring found that telemedicine allowed clinicians to identify symptoms, adjust non-invasive ventilation settings, and maintain a degree of ongoing management during social isolation. Patients reported feeling supported and safe. The researchers were even able to reduce the rate of functional decline in some patients by adjusting ventilatory equipment remotely.11PubMed Central. Assessment of the Clinical and Functional Health Status of Patients with Amyotrophic Lateral Sclerosis during the COVID-19 Pandemic in Brazil Using Telemedicine Other groups proposed toolsets for remote monitoring that could detect disease progression and flag life-threatening changes from a distance.12PubMed Central. Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail Telemedicine clearly proved better than no care at all, and some of its efficiencies are likely to persist. But it did not fully replace the hands-on, multi-specialist model that ALS patients benefit from most.
The Ventilation Dilemma
A specific and uniquely difficult problem arose around non-invasive ventilation, which is the standard of care for ALS patients with respiratory insufficiency. Standard NIV masks are designed with intentional expiratory ports, meaning air escapes from the mask during use. During the pandemic, that design became a liability: those vented masks can aerosolize viral particles, potentially exposing caregivers and family members in the home to SARS-CoV-2. Clinicians recommended immediate modifications, including switching to closed-circuit systems with viral filters, using full-face masks without exhalation ports connected to an expiratory valve, or placing a tightly secured surgical mask over vented masks to reduce aerosol dispersion.13PubMed Central. Modification of non-invasive ventilation for the advanced amyotrophic lateral sclerosis patient during the COVID-19 pandemic – do it now
This was a genuinely difficult trade-off. Stopping or reducing NIV use was not an option for patients who depended on it to breathe. But continuing standard ventilation while potentially infected put every person in the household at risk. The urgency of the recommendation, captured in the paper’s title with the words “do it now,” reflected how quickly this issue needed to be addressed. For many ALS families, especially those without easy access to respiratory equipment suppliers, making these modifications in the early chaotic months of the pandemic was a real logistical challenge.
Psychological Toll on Patients and Caregivers
ALS already carries an enormous emotional burden. Adding a pandemic on top of it compounded the distress in ways that were predictable but no less damaging. Qualitative research with ALS patients and caregivers who participated in self-help groups during the pandemic found that caregivers experienced confusion, sadness, frustration, and anger over the limited time they could devote to their loved ones. For some, that emotional weight escalated into clinical anxiety and depression.14PubMed Central. Amyotrophic Lateral Sclerosis and Its Management during the COVID-19 Pandemic: A Qualitative Study with Thematic Analysis of Patients and Caregivers Who Participated in Self-Help Groups
In the UK, spouses of ALS patients described a layered set of stressors: managing cautious pandemic behavior, dealing with other people’s attitudes toward shielding, and coping with changes to daily life that reflected both pandemic restrictions and ongoing disease progression. Anxiety, depression, and caregiver burden were recurring themes across these interviews. Some spouses also noted behavioral changes in the person with ALS, which is a recognized feature of the disease in some patients and an additional source of strain.15PubMed Central. How the coronavirus pandemic affected the lives of people with ALS and their spouses in the UK from spouses’ perspectives: a qualitative study
An Italian study during the initial lockdown found something worth highlighting: feelings of loneliness in ALS patients were linked more strongly to anxiety and perceived threat from COVID-19 than to the severity of their ALS itself. In other words, it was the pandemic-related isolation and fear, not the disease progression, that was driving the worst of the emotional distress. Caregiver distress, on the other hand, was more closely tied to patient behavioral changes and functional disability. The two members of an ALS household were suffering from overlapping but distinct sources of stress.16Journal of Neurology. Amyotrophic lateral sclerosis patients’ and caregivers’ distress and loneliness during COVID-19 lockdown That distinction matters for intervention planning: patients and caregivers need different kinds of support, even when they are living through the same crisis.
Diagnostic Confusion Around Shared Biomarkers
One quietly important overlap between ALS and COVID-19 involves a blood test called neurofilament light chain, or NfL. In ALS, elevated NfL in the blood is used as a marker of nerve cell damage and is increasingly recognized as a tool for diagnosis and tracking disease progression. When COVID-19 patients were also found to have elevated NfL levels, it raised the question of whether the virus was causing neuronal damage.
Research into this overlap found that NfL elevation in COVID-19 patients tracked more closely with kidney dysfunction than with neurological damage. Serum NfL and creatinine, a standard marker of kidney function, correlated similarly with COVID-19 outcomes, suggesting that NfL rises in severely ill COVID patients largely because the kidneys are not clearing it properly, not because the virus is destroying neurons.17PubMed Central. Serum neurofilament light chain in COVID-19 and the influence of renal function For ALS patients who contracted COVID-19, this creates a practical diagnostic wrinkle: a spike in their NfL levels after infection might reflect systemic illness and kidney stress rather than a genuine acceleration of their neurodegeneration. Clinicians interpreting NfL results in these patients need to account for renal function, which adds a layer of complexity to an already difficult diagnostic picture.
Long COVID and ALS-Like Symptoms
A related area of concern involves people without prior ALS who develop motor neuron symptoms after COVID-19 as part of a long COVID picture. The concept of “long-lasting COVID” includes a wide range of neurological complaints, from fatigue and cognitive fog to more alarming symptoms like progressive weakness. Researchers have noted that the neuroinflammatory pathways activated by SARS-CoV-2 overlap with some of those implicated in ALS, and the question of whether long COVID could occasionally lead to genuine motor neuron disease remains open.4PubMed Central. Amyotrophic Lateral Sclerosis in Long-COVID Scenario and the Therapeutic Potential of the Purinergic System in Neuromodulation
This is still a hypothesis more than a settled finding. Proving that a virus causes or triggers a neurodegenerative disease is extraordinarily difficult, requiring years of follow-up data and large cohorts. The evidence that SARS-CoV-2 can infect motor neurons in the lab, combined with case reports of accelerated ALS progression after infection, provides biological plausibility. But biological plausibility is a starting point, not proof. Many people who develop motor-neuron-like weakness after a severe infection recover, and distinguishing true ALS from post-infectious weakness requires careful clinical evaluation over time. The concern is real enough to warrant ongoing surveillance, particularly as the long COVID population ages and enough time passes for slowly developing neurodegenerative conditions to declare themselves.